ArticleLeukemia2018
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Article in Leukemia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 62 citations in OpenAlex.
- High-risk genomic features predict extramedullary progression in multiple myeloma with paraskeletal plasmacytomas.HemaSphere · 2026Article
- Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: results from HALO-Taiwan subset.Journal of gynecologic oncology · 2026Article
- From Germline Susceptibility to Therapeutic Vulnerability: DNA Damage Response Gene Mutations Driving Multiple Myeloma Evolution and Precision Therapy.Human mutation · 2026Review
- Germline predisposition in multiple myeloma.iScience · 2025Article
- The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study.BMC cancer · 2024Article
- Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study.International journal of molecular sciences · 2024Article
- Targeting the DNA damage response in hematological malignancies.Frontiers in oncology · 2024Review
- Assessing the Phenotype of a Homologous Recombination Deficiency Using High Resolution Array-Based Comparative Genome Hybridization in Ovarian Cancer.International journal of molecular sciences · 2023Article
- Multi-scale characterisation of homologous recombination deficiency in breast cancer.Genome medicine · 2023Article
- TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma.Journal of experimental & clinical cancer research : CR · 2023Article
- Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma.Blood cancer journal · 2023Article
- Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma.Genes · 2023Article
- Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway.Blood cancer journal · 2023Article
- ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.International journal of cancer · 2022Article
- Multi-omics data integration analysis identifies the spliceosome as a key regulator of DNA double-strand break repair.NAR cancer · 2022Article
- Multiple myeloma with high-risk cytogenetics and its treatment approach.International journal of hematology · 2022Review
- The Role of DNA Repair in Genomic Instability of Multiple Myeloma.International journal of molecular sciences · 2022Review
- Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas.NPJ precision oncology · 2022Article
- Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.NPJ breast cancer · 2022Article
- Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PARP inhibitors can induce synthetic lethality in tumors characterized by homologous recombination deficiency (HRD), which can be detected by evaluating genome-wide loss of heterozygosity (LOH). Multiple myeloma (MM) is a genetically unstable tumor and we hypothesized that HRD-related LOH (HRD-LOH) could be detected in patient samples, supporting a potential role for PARP inhibition in MM. Using results from targeted next-generation sequencing studies (FoundationOne
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.